Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Open Access
- 1 August 2020
- journal article
- research article
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 42 (4) , 431-441
Abstract
The prevalence of Alzheimer's disease (AD), a progressive neurodegenerative disorder, is expected to more than double by 2050. Studies on the pathophysiology of AD have been changing our understanding of this disorder and setting a new scenario for drug development and other therapies. Concepts like the "amyloid cascade" and the "continuum of AD," discussed in this article, are now well established. From updated classifications and recommendations to advances in biomarkers of AD, we aim to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject. Updates on the status of major clinical trials are also given, and future perspectives are discussed.Keywords
This publication has 139 references indexed in Scilit:
- Effect of TTP488 in patients with mild to moderate Alzheimer’s diseaseBMC Neurology, 2014
- Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer’s diseaseBrain, 2013
- Preclinical Alzheimer disease—the challenges aheadNature Reviews Neurology, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Hippocampal sclerosis in advanced age: clinical and pathological featuresBrain, 2011
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Diagnosis and biomarkers of predementia in Alzheimer's diseaseBMC Medicine, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Alzheimer's diseaseThe Lancet, 2006